Clinical Trials · NCT07596212

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Name: BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingPhase 1/Phase 2Gonadorelin

Phase: Phase 1/Phase 2
Recruitment status: Not Yet Recruiting
Sponsor: University of Illinois at Chicago
Enrollment: 100
Start date: Sep 2026
Locations: 1 site, United States
Primary endpoint: Tolerance of study drugs in patients with early stage breast cancer and Hypoactive Sexual Desire Disorder

View Gonadorelin compound reference